Vitrectomy with or without encircling band for pseudophakic retinal detachment: a multi-centre, three-arm, randomised clinical trial. VIPER Study Report No. 1—design and enrolment

B Mazinani,1 S Baumgarten,1 P Schiller,2 H Agostini,3 H Helbig,4 E Limburg,5 M Hellmich,2 P Walter,1 for the VIPER Study Group

ABSTRACT

Purpose Scleral buckling is currently used in addition to vitrectomy for the treatment of pseudophakic retinal detachment (PRD) to better support the vitreous base and better visualisation of the periphery. The aims of this study are to evaluate (1) whether the combination of 20 G vitrectomy and scleral buckling is superior to 20 G vitrectomy alone (control) (confirmatory), and (2) whether transconjunctival 23/25 G vitrectomy is non-inferior to 20 G vitrectomy (both without scleral buckling) regarding operation success (exploratory).

Methods The VIPER (Vitrectomy plus Encircling Band Versus Vitrectomy Alone for The Treatment of Pseudophakic Retinal Detachment) study is an unmasked, multi-centre, three-arm randomised trial. Patients with PRD were eligible, excluding complicated retinal detachment or otherwise severe ophthalmologic impairment. Patients were randomised to one of three interventions: 20 G vitrectomy alone (control C), combination of 20 G vitrectomy and circumferential scleral buckling (experimental treatment E1) or 23/25 G vitrectomy alone (experimental treatment E2). The primary endpoint is the absence of any indication for a retina re-attaching procedure during 6 months of follow-up. Secondary endpoints include best corrected visual acuity, retina re-attaching procedures, complications and adverse events.

Results From June 2011 to August 2013, 257 patients were enrolled in the study. The internet randomisation service assigned 100 patients each to the treatment arms C and E1, and 57 patients to treatment E2.

The imbalance is due to the fact that several retinal surgeons did not qualify for performing E2. The randomisation assignment was stratified and balanced (ie, 1:1 or 1:1:1 ratio) by surgeon.

Conclusions The described study represents a methodologically rigorous protocol evaluating the benefits of three different vitrectomy approaches to PRD. The projected results will help to establish their overall efficacy and will permit conclusions regarding their relative value.

Trial registration number DRKS00003158 (German Clinical Trials Register, DRKS).

INTRODUCTION

Background and rationale

Vitrectomy has been combined with scleral buckling in the treatment of pseudophakic retinal detachment (PRD) ever since vitrectomies have been used to treat this disorder. Retinal surgeons expect additional buckling procedures to provide enhanced support of the vitreous base and better visualisation of the periphery. On the other hand, the additional scleral buckle implies increased invasivity and operation time, it affects the postoperative refraction and the blood circulation of the eye1 and may entail specific complications such as buckle migration and infection. The literature is inconclusive regarding the question whether these costs of the additional buckle are associated with increased anatomical or functional success. While some studies reported almost complete success of combined surgery,2,3 other studies comparing vitrectomy versus vitrectomy with additional buckle found no benefit of the latter. Pournaras and Kapetanios achieved excellent re-attachment rates with both techniques (ie, 100% vs 92% at first attempt).4 Wickham and coauthors compared vitrectomy alone with vitrectomy and scleral buckling in cases with inferior breaks. In both groups, about half of the patients were pseudophakic: 54% and 53%, respectively. The primary re-attachment rate was 89% in the vitrectomy alone group and 73% in the vitrectomy plus buckle group.5 Stangos and coauthors compared vitrectomy alone with vitrectomy plus scleral buckling for PRD. The re-attachment rate was 97% in the vitrectomy alone group and 92% in the vitrectomy plus buckle group.6 Recently, data on 4179 patients with retinal detachment have been published based on surveys among retinal surgeons. A subgroup analysis showed a slightly higher failure rate for combined surgery versus vitrectomy alone; however, bias due to differential selection of cases (eg, favouring an additional buckle in difficult situations) cannot be ruled out.7 All these studies were either retrospective or prospective non-randomised trials. The scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment (SPR) study was a prospective randomised multi-centre trial to compare vitrectomy and scleral buckling in the treatment of phakic or pseudophakic patients with retinal detachment of medium complexity.8 An ancillary analysis showed that in pseudophakic patients treated with vitrectomy the use of an additional buckle resulted in a significantly lower re-detachment rate of 11.4% versus 40.9% in patients who were treated by vitrectomy alone. However, the use of an additional buckle was not randomly assigned but at the discretion of the treating surgeon. In recent years, transconjunctival 23 G or 25 G surgery has been replacing the 20 G approach with exposition of the sclera. Several
retrospective studies found similar results of the two techniques in the treatment of retinal detachment.9–13 Again, evidence from randomised trials is still lacking.

Objectives
The primary objective of the VIPER (Vitrectomy Plus Encircling Band Vs. Vitrectomy Alone For The Treatment Of Pseudophakic Retinal Detachment) study is to test the superior efficacy of an additional encircling band in addition to a 20 G vitrectomy with gas (treatment codes E1 and C) in the treatment of PRDs (confirmatory). The primary endpoint is the absence of any situation leading to an additional retina re-attaching surgical procedure during the follow-up. The secondary objective is to investigate whether 23/25 G transconjunctival vitrectomy with gas (E2) is not inferior to 20 G vitrectomy with gas (C) in the treatment of PRD without encircling band (exploratory).

Trial design
VIPER is a multi-centre, randomised clinical trial with three parallel treatment arms (see figure 1); however, each comparison (superiority, non-inferiority) is based on two arms only (ie, E1 vs C, and E2 vs C, respectively). As the study treatments are different surgical procedures, blinding of the trial surgeons is not possible. Given the specific side effects of the additional encircling band such as myopic shift of about 2 D and possible complications such as infection, strabismus, explant intrusion and others, patient blinding is not possible either. The study protocol is available as supplementary file.

PARTICIPANTS AND METHODS
Study setting
Patients were enrolled at 14 trial centres specialised on retinal surgery. The participating institutions are university clinics that provide emergency care and treat the majority of regional cases of PRD.

Eligibility criteria
Pseudophakic patients over 18 years of age were eligible if they suffered from a rhegmatogenous retinal detachment and gave written informed consent. Cataract surgery had to be done at least 3 months before the onset of symptoms of retinal detachment. The main exclusion criteria were manifest uveitis, uncontrolled glaucoma, active retinal vascular disease, malignant intraocular tumours, any history of intraocular surgery other than (distant) cataract surgery, giant retinal tears, proliferative vitreoretinopathy grade B or C, aphakia and any systemic disorder potentially preventing (i) local/general anaesthesia or (ii) participation in the control examinations.

Interventions
Control group (C): Patients who were randomly assigned to the control group received a 20 G vitrectomy without encircling band. Surgery was performed with an operating microscope and a wide field viewing system (contact/non-contact). The conjunctiva was opened at the limbus to expose the sclera. Three 20 G sclerotomies were made with a distance of 3–4 mm to the

Figure 1 Design of the VIPER study.
limbus. A full vitrectomy was performed. If the vitreous was not fully detached, a complete vitreous detachment was achieved. Heavy liquids were allowed to drain subretinal fluid. After full re-attachment of the retina under heavy liquids or under air, each retinal break was treated with endolaser or transscleral cryopexy. Peripheral high-risk degenerations should be treated as well. A prophylactic circumferential laser treatment was not allowed. The surgery was completed with a gas fill using non-expandable air/gas mixtures such as SF6, C2F6 or C3F8 and closure of the sclerotomies and the conjunctiva. Ocular pressure had to be monitored at least once within 8 h after surgery and the day after surgery. If the intraocular pressure exceeded 40 mm Hg, gas should be released via the pars plana using sterile techniques.

Experimental group 1 (E1): Patients in this group received a 20 G vitrectomy with an encircling band. Surgery started with a circumferential opening of the conjunctiva at the limbus. A 2–4 mm encircling band was placed underneath the recti muscles and was fixated in all four quadrants. The encircling band was positioned onto the equator of the globe. At the end of surgery, sufficient buckling with no choroidal folds should be visible. The 20 G vitrectomy was performed as described above for the control group (C).

Experimental group 2 (E2): Patients in this group were treated with a 23 G or 25 G vitrectomy without an encircling band. A full vitrectomy was performed using valved or unvalved transconjunctival trocar systems. Trocars were inserted tangentially after displacement of the conjunctiva. If not yet present a full vitreous detachment should be achieved. Endodrainage of the subretinal fluid was achieved with the use of heavy liquids and/or air. After full re-attachment of the retina, breaks and high-risk degenerations were treated with the endolaser probe or with transconjunctival/transscleral cryopexy. A circumferential prophylactic laser treatment was not allowed. After full fluid-air exchange, the eye was filled with a non-expandable air/gas mixture. Trocars were removed. If the sclerotomies were leaking, they had to be sutured either transconjunctivally or after opening of the conjunctiva.

All groups (C, E1, E2): In none of the groups, the use of silicone oil, internal limiting membrane peeling or triamcinolone was allowed. Medical treatment could be given by the decision of the surgeon and according to institutional standards.

Outcomes
The primary endpoint was defined as the absence of an indication for any retina re-attaching procedure during the follow-up. Retina re-attaching procedures were additional gas injection, additional vitrectomy or additional buckling procedure. The presence of any such indication was regarded as treatment failure. Generally, functional (eg, visual acuity) or anatomic (as in this study) endpoints are possible to assess treatment success in retinal detachments. In our opinion, visual acuity is not a valid parameter because patients with retinal detachment present in emergency settings during the night or on weekends possibly with a dilated pupil which may affect preoperative EFTRS visual acuity testing. In fact almost all studies on retinal detachment use anatomical endpoints. Further, supporting (secondary) endpoints on efficacy and safety are given in table 1.

After completion of the study follow-up, all documented clinical data (including fundus drawings and photographs) were evaluated by a clinical endpoint committee (SB, BM, PW) regarding the incidence of key study events.

Participant timeline
Following inclusion of a patient in the study, randomisation and surgery, patients were examined after 6, 12 and 26 weeks (see table 2).

Sample size
In the SPR study, 11.4% (=10/88) of pseudophakic patients who had received combined primary vitrectomy and scleral buckling suffered from a re-detachment, in contrast to 40.9% (=18/44) of pseudophakic patients who received primary vitrectomy only. We calculated 82 patients per group (E1, C) (software PS V3.0.43; http://biostat.mc.vanderbilt.edu/PowerSampleSize) for the continuity corrected χ² test to have 80% power at two-sided type 1 error rate of 5% assuming event proportion of 35% (E1) and 15% (C). According to Donner (1984), about 10% inflation seems adequate to account for the stratification (ie, 91≈82/

d | Table 1 | Key secondary endpoints evaluated in the VIPER study |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Endpoint</td>
<td>Measurement variable</td>
<td>Analysis metric</td>
<td>Method of aggregation</td>
<td>Time</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual acuity</td>
<td>LogMAR visus using ETDRS charts</td>
<td>Change from baseline</td>
<td>Means</td>
<td>At 26 weeks post-surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refractive status</td>
<td>Sphere (D), cylinder (D), axis (°A)</td>
<td>Change from baseline</td>
<td>Means</td>
<td>At 26 weeks post-surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraocular pressure</td>
<td>Tonometry (mm Hg)</td>
<td>Change from baseline</td>
<td>Means</td>
<td>At 26 weeks post-surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retina re-attachment</td>
<td>…</td>
<td>Value (yes/no)</td>
<td>Proportions</td>
<td>At surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retina-specific procedures</td>
<td>… to achieve a stable retinal attachment</td>
<td>Value (yes/no)</td>
<td>Centiles</td>
<td>At 26 weeks post-surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proliferative vitreoretinopathy grade C</td>
<td>… according to Machemer</td>
<td>Value (yes/no)</td>
<td>Proportions</td>
<td>Within 26 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operation time</td>
<td>Time between cut and suture</td>
<td>Value (yes/no)</td>
<td>Proportions</td>
<td>Within 26 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anatomical situation</td>
<td>… of lids, conjunctiva, cornea, anterior chamber, iris, intraocular lens or vitreous cavity</td>
<td>Value (yes/no)</td>
<td>Proportions</td>
<td>At surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraoperative complications</td>
<td>… as iatrogenic breaks, bleeding, scleral perforation</td>
<td>Value (yes/no)</td>
<td>Centiles</td>
<td>Within 26 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postoperative complications</td>
<td>… as macular pucker, macular oedema, ocular hypertension, diploria</td>
<td>Value (yes/no)</td>
<td>Centiles</td>
<td>Within 26 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enucleation</td>
<td>…</td>
<td>Value (yes/no)</td>
<td>Proportions</td>
<td>Within 26 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>…</td>
<td>Time to event</td>
<td>Centiles</td>
<td>Within 26 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Another 10% was added to account for invaluable patients (ie, 100≈91/0.9). After reaching this target, recruitment to the whole trial was stopped, that is, when, according to expectation, about 33 patients would have been allocated to group E2.

Expecting an event percentage of 35% for treatment C, we considered a difference smaller than 5 percentage points clinically non-inferior. This corresponds to an OR of about 1.25 which was used as the non-inferiority margin for the comparison of treatments C and E2. Assuming event percentages of 35% in both arms and a non-inferiority bound of 5 percentage points, 1427 patients per treatment arm are required to reach 80% power at 2.5% one-sided type I error rate (calculated with R V.3.0.3, package gsDesign, function nBinomial). Such a big trial seems unfeasible, thus the comparison of C and E2 can be explorative only.

The issue of an ‘underpowered comparison’ was also raised by the local ethics committee. We argued that little evidence of high quality (ie, based on a small number of randomised patients) (i) is better than no evidence at all, at least for the time being, and (ii) may later be incorporated in a meta-analysis of similar cases. This argumentation was approved upon by the local ethics committee. Note also that E2 has already become popular (eg, due to shorter operation time, less postoperative discomfort and logistics) without any evidence from randomised trials.

Methods against bias
Selection bias is minimised by central 24/7 internet randomisation. Performance bias is minimised by standardisation of trial treatments and including only experienced surgeons. Note that masking of patients or surgeons is not possible. Attrition bias is minimised by provision of excellent care and dedicated follow-up efforts. Detection bias is minimised by using standardised outcome assessment, for example, based on ETDRS visual charts. Note that masking of outcome assessors (ie, the clinical endpoint committee) is generally not possible (eg, due to fundus drawings/photographs).

Data collection and management
All patient data were remotely entered by clinical centre staff into a validated (ie, US Food And Drug Administration 21 Code
of Federal Regulations Part 11 compliant) electronic database and checked for plausibility and completeness (central monitoring). Moreover, fundus drawings and 9-field fundus photographs were sent to the coordinating investigator. On-site monitoring could not be performed due to limited funding. Access to the database was restricted to the participating surgeons and monitors. The access of the surgeons was restricted to their own patients. Patient data were pseudonymised.

Statistical methods
Three trial populations are evaluated: (i) intention-to-treat (ITT) population (all trial subjects enrolled and randomised; analysis as assigned), (ii) per-protocol (PP) population (all trial subjects treated and observed according to protocol) and (iii) the as-treated (AT) population (all trial subjects enrolled and randomised; analysis as treated). The primary analysis of E1 versus C (superiority) is derived from the ITT principle, that is, all patients randomised are analysed as assigned. A missing primary endpoint is considered a treatment failure. Otherwise (secondary) the last observation may be carried forward and/or multiple imputation may be done. For the exploratory comparison of E2 versus C (non-inferiority), the analyses based on the ITT analysis set and the PP analysis set are considered equally important.16 Further details are laid out in the statistical analysis plan (see Supplementary file).

The primary target variable is the number of patients with ‘absence of an indication for any retina re-attaching procedure within 26 weeks after surgery’. The treatment comparison E1 versus C is evaluated for superiority by the Cochran–Mantel–Haenszel test stratified by surgeon and the corresponding common OR.17 Heterogeneity due to surgeon (ie, treatment by surgeon interaction) is tested by the Breslow–Day test. Any significant heterogeneity is attempted to be explained by relevant covariates. For the exploratory comparison of E2 versus C, a non-inferiority margin of 1.25 (OR) is employed. Logistic regression and multiple imputation methods are used for sensitivity analysis.

The secondary endpoints are evaluated by Cochran–Mantel–Haenszel methods (nominal variables) or linear models (metric variables), respectively, stratified by surgeon. Mixed models for repeated measures, generalised estimating equations and multiple imputations methods are used for sensitivity analysis. Safety data, that is, adverse events and/or complications, are summarised by type, seriousness, intensity, relatedness and the treatment performed. A subgroup analysis is done with respect to sex (the expected proportion of men is 73%). No formal interim analysis was planned.

Ethical and legal aspects
The study was designed and conducted according to the principles of Good Clinical Practice (GCP, ICH E6) and data protection laws. Important protocol modifications can only be made if agreed by the coordinating investigator, the project manager and the statisticians and all authors of the trial protocol. Any changes must be made in writing and must be documented with reasons. They will be signed by all authors of the original trial protocol. Amendments that require approval are submitted to the ethics committee and will not be implemented until approved. Exceptions to this are amendments made to avoid immediate dangers.

The study was prospectively registered in the German Clinical Trials Register under DRKS00003158.

It is planned to publish the trial results, in mutual agreement with the Principal Coordinating Investigator (PCI), in a scientific journal and at German or international congresses. Publication of the results of the trial as a whole is intended. Any publication will take account of the ‘Uniform requirements for manuscripts submitted to biomedical journals (International Committee of Medical Journal Editors)’.18

---

**Figure 2** Enrolment of patients over time.

Clinical science

Trial status
Overall, 14 centres and 34 surgeons participated in the study. 18 surgeons enrolled only in arms E1 and C with allocation ratio 1:1 and 16 surgeons enrolled in all three arms, including 23/25 G vitrectomy with gas (E2) with ratio 1:1:1. During the enrolment phase from June 2011 to August 2013, a total of 237 patients with PDR were included (see figure 2), 100 patients were randomly assigned to arm E1, 57 patients to arm E2 and 100 patients to arm C, respectively. Because the surgeons who were proficient in all three techniques tended to recruit more patients than expected, that is, eventually 57 instead of 33 patients as given in the protocol, the local ethics committees were timely asked for reapproval which they granted.

SUMMARY AND CONCLUSION
The additional implantation of a scleral buckle in the treatment of retinal detachments with vitrectomy implies an additional trauma. The 360° incision of the conjunctiva and exposition of the sclera lead to consecutive scarring and surface alterations and the impact of the buckle on the shape of the eye results in a significant myopisation. The VIPER study will demonstrate whether the additional risks of a circumferential scleral buckle combined with vitrectomy are justified by a superior success rate. Moreover, in view of the increasing use of transconjunctival vitrectomy to treat retinal detachments, it seems mandatory to investigate whether patients benefit from an additional buckle before this technique is, possibly prematurely, abandoned due to technical progress.

Trial organisation
Coordinating investigator is Peter Walter, Department of Ophthalmology, University of Aachen (RWTH). Project coordination, correspondence with regulatory authorities, data management and central monitoring were performed by the Clinical Trials Centre Cologne (ZKS Köln), University of Cologne. Statistical design, randomisation and data analysis were performed by the Institute of Medical Statistics, Informatics and Epidemiology (IMSI), University of Cologne. Trial procedures were implemented according to the standard operating procedures of ZKS Köln and IMSIE.

Collaborators Vnger Study Group Surgeons, in alphabetical order: Agostini H (Freiburg), Asenbreys T (Tübingen), Bartz-Schmidt U (Tübingen), Bornfeld N (Essen), Clemons C (Münster), Dahike C (Cologne), Eter N (Münster), Fauser S (Cologne), Fellgren N (Göttingen), Gamulescu MA (Regensburg), Gök M (Essen), Hellbig H (Regensburg), Hillenkamp J (Kiel), Holz F (Bonn), Jochemm C (Leipzig), Jousen A (Berlin), Junker B (Freiburg), Kirchhof B (Cologne), Lappas A (Cologne), Lommatzsch A (Münster), Lüke M (Lübeck), Mazinani B (Aachen), Meier P (Leipzig), Neß T (Freiburg), Nestler A (Leipzig), Partsch M (Tübingen), Piepen A (Freiburg), Rasche W (Leipzig), Ritzau-Tondrow U (Göttingen), Rössler G (Aachen), Rössler J (Kiel), Rudolf M (Leipzig), Schillier P (Cologne). Project management: Limburg E (Cologne), Well C (Cologne).

Contributors The following persons have contributed to the planning, conduct and reporting of the study: BM, SB, PS, HA, HH, EL, MH and PW.

Funding The study was supported by retina.net, the German Competence Network for Clinical Studies in Vitreoretinal Surgery. retina.net received grants from the Jackstädt Foundation, the German Retina Society and the German Ophthalmological Society (DOG). Moreover, ZKS Köln was supported by BMBF grant 01KN1106. These funders had no participation in or authority on study design, data or writing of the report.

Competing interests None declared.

Patient consent Obtained.

Ethics approval The local ethics committees of all participating institutions.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/